共查询到19条相似文献,搜索用时 125 毫秒
1.
多肽、蛋白类药物脂质体的研究进展 总被引:1,自引:0,他引:1
脂质体做为多肽、蛋白类药物一种新型给药载体有控制药物释放、降低药物的毒性、提高药物的靶向性等突出优点,具有广阔的应用前景。本文通过查阅近10年来多肽和蛋白类药物脂质体研究的相关资料,总结论述了脂质体作为多肽、蛋白类药物载体在新的制备方法、新型脂质体、给药途径、产业化进展四个方面的最新研究动向,指出了多肽、蛋白类药物脂质体在研究应用中存在的不足,并展望了多肽、蛋白类药物脂质体未来发展的方向。 相似文献
2.
3.
李盈娄月芬 《现代生物医学进展》2012,12(19):3762-3765
相对于其他的给药途径,蛋白质多肽类药物的口服、经鼻、肺部给药途径更具可行性和商业价值。利用制剂学方法可提高蛋白质多肽类药物生物利用度。通过蛋白多肽类给药系统的评价,对近年来国内外此类药物在剂型、体内外稳定性及生物利用度等方面的研究进展予以综述。 相似文献
4.
5.
融合蛋白技术应用于生物制药行业已超过25年,其目的为改善原来天然蛋白的性质,从而具有新的理化特征和生物学功能,其中最为显著的特点是改善了小分子蛋白及多肽半衰期短的缺陷。基于该技术所诞生的融合蛋白类药物已成为当前生物药研发的热点。结合已上市融合蛋白类药物,通过与传统多肽蛋白类药物比较,重点突出融合蛋白类药物自身特点,主要从融合抗体Fc段和人血清白蛋白以延长小分子蛋白及多肽半衰期的角度对融合蛋白药物长效化策略进行评述;对融合蛋白类药物在体内的吸收、分布、代谢和排泄的显著特征进行概述;综述该类药物在体内的分析技术并指出当前分析技术的优缺点及发展方向,为长效化融合蛋白药物的设计、分析研究与开发提供依据和思路。 相似文献
6.
环糊精及其衍生物在多肽/蛋白质类药物非注射给药体系中的应用 总被引:1,自引:0,他引:1
目前,多肽/蛋白质类药物多数需要采用注射剂型给药以确保其生物利用度。开发易于给药、病人顺应性高以及治疗费用更低的非注射剂型是非常有意义的。然而,多肽/蛋白质类药物直接进行非注射给药的生物利用度通常非常低,需要制备具有设计功能的载药系统,例如加入不同比例的酶抑制剂、吸收促进剂等以提高生物利用度。环糊精及其衍生物由于其能与客体分子形成包合物的特性,以及对粘膜的促渗透作用等,在多肽/蛋白质药物的非注射给药系统中获得了日益广泛的应用。综述了近年来环糊精及其衍生物在多肽/蛋白质类药物非注射给药体系中的应用情况。 相似文献
7.
多肽类药物制剂研究现状 总被引:1,自引:0,他引:1
多肽类药物制剂研究所面临的主要问题是多肽的不稳定性、体内半衰期短和生物膜透过性差。本文综述了(1)引起多肽不稳定性的原因;(2)提高多肽稳定性的方法;(3)多肽类药物制剂货架时间的确定;(4)多肽类药物的分析手段;(5)多肽类药物的控释研究;(6)多肽的非注射途径给药研究。最后提出了多肽类药物制剂研究的展望。 相似文献
8.
随着基因工程技术的发展,蛋白质多肽药物的应用越来越受到人们的青睐。但此类药物具有血浆半衰期较短、免疫原性较强等不足
之处,在很大程度上限制了其临床应用。因此,研究人员尝试采用各种化学方法对蛋白质多肽类药物加以修饰,以弥补这一不足。与 PEG 修饰、
糖基化修饰、定点突变等方法相比,脂肪酸修饰除了可获得良好的生物活性、提高稳定性、降低免疫原性外,更重要的是由于脂肪酸是构
成人体脂肪、类脂和细胞膜磷脂的重要成分,可有助于提高药物的脂溶性,增大肠道黏膜透过性,增强药物与受体的结合。对蛋白质多肽
药物的脂肪酸修饰研究进展进行综述。 相似文献
9.
近些年,随着多肽合成工艺逐步成熟和药物制剂技术不断提升,多肽类药物受到国内、外研究者的广泛关注,与之有关的研发工作陆续展开。临床医学中,多肽类药物主要用于治疗肿瘤、糖尿病、骨质疏松症等多种复杂疾病,应用价值较高。在健康理念越来越受到人们重视之际,摸清多肽类药物当前的发展现状是非常有必要的,并且要对制剂学上暴露的问题展开探究,这是文章研究的重点,最后对多肽类药物制剂的研究进行展望,提出的观点、阐述的策略仅供参考。 相似文献
10.
基因工程蛋白和多肽药物是第一代基因工程药物的主体,已广泛应用于临床,但这类药物的血浆半衰期一般只有数十分钏至数小时,疾病治疗时往往需要反复频繁注射, 相似文献
11.
12.
Nose-to-brain (N-to-B) delivery offers to protein and peptide drugs the possibility to reach the brain in a non-invasive way. This article is a comprehensive review of the state-of-the-art of this emerging peptide delivery route, as well as of the challenges associated to it. Emphasis is given on the potential of nanosized drug delivery carriers to enhance the direct N-to-B transport of protein or peptide drugs. In particular, polymer- and lipid- based nanocarriers are comparatively analyzed in terms of the influence of their physicochemical characteristics and composition on their in vivo fate and efficacy. The use of biorecognitive ligands and permeation enhancers in order to enhance their brain targeting efficiency is also discussed. The article concludes highlighting the early stage of this research field and its still unveiled potential. The final message is that more explicatory PK/PD studies are required in order to achieve the translation from preclinical to the clinical development phase. 相似文献
13.
By the introduction of various amide surrogates, novel pseudopeptides corresponding to a membrane active depsipeptide were synthesized and their native characteristics compared with that of the peptide. The pseudopeptides had more resistance to serum proteases than the peptide and similar antimicrobial activities to that of the peptide without hemolytic activity. The pseudopeptides like the peptide were active against current drug resistant fungi and pathogenic fungi isolated from patients, and also had a strong synergism with current antifungal drugs against Candida albicans. The leakage assay suggested that the pseudopeptides also acted on the lipid membrane of pathogenic cells. These results indicated that the novel pseudopeptides had advantages over the peptide as a candidate for a novel antifungal drug and backbone modifications can be a tool in the development of a novel antifungal agent from membrane-active peptides isolated from natural sources or chemically synthesized. 相似文献
14.
Bárbara Gomes Marcelo T. Augusto Mário R. Felício Axel Hollmann Octávio L. Franco Sónia Gonçalves Nuno C. Santos 《Biotechnology advances》2018,36(2):415-429
Infectious diseases are one of the main causes of human morbidity and mortality. In the last few decades, pathogenic microorganisms' resistance to conventional drugs has been increasing, and it is now pinpointed as a major worldwide health concern. The need to search for new therapeutic options, as well as improved treatment outcomes, has therefore increased significantly, with biologically active peptides representing a new alternative. A substantial research effort is being dedicated towards their development, especially due to improved biocompatibility and target selectivity. However, the inherent limitations of peptide drugs are restricting their application. In this review, we summarize the current status of peptide drug development, focusing on antiviral and antimicrobial peptide activities, highlighting the design improvements needed, and those already being used, to overcome the drawbacks of the therapeutic application of biologically active peptides. 相似文献
15.
《基因组蛋白质组与生物信息学报(英文版)》2022,20(4):780-794
After decades of development, protein and peptide drugs have now grown into a major drug class in the marketplace. Target identification and validation are crucial for the discovery of protein and peptide drugs, and bioinformatics prediction of targets based on the characteristics of known target proteins will help improve the efficiency and success rate of target selection. However, owing to the developmental history in the pharmaceutical industry, previous systematic exploration of the target spaces has mainly focused on traditional small-molecule drugs, while studies related to protein and peptide drugs are lacking. Here, we systematically explore the target spaces in the human genome specifically for protein and peptide drugs. Compared with other proteins, both successful protein and peptide drug targets have many special characteristics, and are also significantly different from those of small-molecule drugs in many aspects. Based on these features, we develop separate effective genome-wide target prediction models for protein and peptide drugs. Finally, a user-friendly web server, Predictor Of Protein and PeptIde drugs’ therapeutic Targets (POPPIT) (http://poppit.ncpsb.org.cn/), is established, which provides not only target prediction specifically for protein and peptide drugs but also abundant annotations for predicted targets. 相似文献
16.
John J. Turner 《生物化学与生物物理学报:生物膜》2006,1758(3):290-300
New candidates for development as potential drugs or virucides against HIV-1 infection and AIDS continue to be needed. The HIV-1 RNA leader sequence has many essential functional sites for virus replication and regulation that includes several highly conserved sequences. The review describes the historical context of targeting the HIV-1 RNA leader sequence with antisense phosphorothioate oligonucleotides, such as GEM 91, and goes on to describe modern approaches to targeting this region with steric blocking oligonucleotide analogues having newer and more advantageous chemistries, as well as recent studies on siRNA, towards the attainment of antiviral activity. Recent attempts to obtain improved cell delivery are highlighted, including exciting new developments in the use of peptide conjugates of peptide nucleic acid (PNA) as potential virucides. 相似文献
17.
Turner JJ Fabani M Arzumanov AA Ivanova G Gait MJ 《Biochimica et biophysica acta》2006,1758(3):290-300
New candidates for development as potential drugs or virucides against HIV-1 infection and AIDS continue to be needed. The HIV-1 RNA leader sequence has many essential functional sites for virus replication and regulation that includes several highly conserved sequences. The review describes the historical context of targeting the HIV-1 RNA leader sequence with antisense phosphorothioate oligonucleotides, such as GEM 91, and goes on to describe modern approaches to targeting this region with steric blocking oligonucleotide analogues having newer and more advantageous chemistries, as well as recent studies on siRNA, towards the attainment of antiviral activity. Recent attempts to obtain improved cell delivery are highlighted, including exciting new developments in the use of peptide conjugates of peptide nucleic acid (PNA) as potential virucides. 相似文献
18.
Therapeutic peptides 总被引:2,自引:0,他引:2
Novel peptide therapeutics are increasingly making their way into clinical application. Indeed, certain naturally derived peptides have been successful drugs for many years. With the advent of large biological and synthetic peptide libraries and high-throughput screening, many promising candidates could soon be added to the list of peptides under development. These advances have introduced new strategies for the administration of peptide drugs and improvements of clearance half-lives in vivo. Despite the potential obstacles that remain, peptide therapeutics are poised to play a significant role in the treatment of diseases ranging from Alzheimer's disease to cancer. 相似文献
19.
Bioactive peptides are important therapeutic drugs, yet conventional methods of peptide synthesis are challenged to meet increasing demand. We developed a novel and efficient means of metabolic engineering: therapeutic peptide production in Drosophila and as a proof of concept, we demonstrate production of fully matured human insulin. This in vivo system offers an innovative means to produce valuable bioactive peptides for therapies, its inherent flexibility facilitates drug development, and its ease of producing fully processed peptides simplifies metabolic engineering of new peptide products. 相似文献